Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.

Published on Jan 1, 2020in Diabetes, Obesity and Metabolism5.9
· DOI :10.1111/DOM.13870
Ele Ferrannini110
Estimated H-index: 110
Simona Baldi32
Estimated H-index: 32
(UniPi: University of Pisa)
+ 5 AuthorsRalph A. DeFronzo182
Estimated H-index: 182
(University of Texas Health Science Center at San Antonio)
AIM: To determine the effects of individual and combined therapies on plasma insulin, glucagon, β-hydroxybutyrate (β-OH) and associated metabolites. MATERIALS AND METHODS: In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb. The study included 678 patients randomized 1:1:1 to EQW + Dapa, EQW + Plb, or Dapa + Plb. Plasma insulin and glucagon were measured at fasting and 2 hours after a mixed meal. Fasting plasma free fatty acids (FFA) and β-OH concentrations were measured. RESULTS: The fasting insulin-to-glucagon molar ratio (I/Glg) increased with EQW + Plb only; postprandial I/Glg increased in all groups but significantly more with EQW + Plb. β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa. β-OH levels and I/Glg were inversely related to one another. Patients in the top quartile of β-OH changes from baseline [median (interquartile range): +207 (305) vs. -65 (-154) μmol/L; P < .0001] were more frequently treated with Dapa + Plb, had higher urine glucose-to-creatinine ratios, and lower fasting insulin [52 (51) vs. 68 (53) pmol/L; P = .0013) and I/Glg [1.76 (1.49) vs. 2.23 (1.70) mol/mol; P = .0020]. Haematocrit increased only in the Dapa group. CONCLUSIONS: The EQW + Dapa combination abolished the Dapa-induced rise in β-OH, reduced the EQW-induced increase in I/Glg, maintained glycosuria, and increased haematocrit in patients with poorly controlled type 2 diabetes. The drug combination may preserve any putative benefits while mitigating the risk of ketoacidosis.
📖 Papers frequently viewed together
5 Citations
201916.02Diabetes Care
6 Authors (Tina Vilsbøll, ..., Marcus Lind)
4 Citations
17 Citations
#1Serge Jabbour (Thomas Jefferson University)H-Index: 25
#2Juan P. FriasH-Index: 26
Last. Cristian Guja (UMFCD: Carol Davila University of Medicine and Pharmacy)H-Index: 23
view all 7 authors...
OBJECTIVE Among patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin combination produced greater reductions in glycemia, weight, and systolic blood pressure (SBP) at 28 weeks than exenatide QW or dapagliflozin alone (DURATION-8). Here, we investigated the safety and maintenance of efficacy at 52 weeks, after a 24-week extension. RESEARCH DESIGN AND METHODS This phase 3, multicenter, double-blind study randomized adults with type 2 diabetes (wi...
42 CitationsSource
#1David Polidori (Janssen Pharmaceutica)H-Index: 28
#2Hiroaki Iijima (Mitsubishi Tanabe Pharma)H-Index: 11
Last. Peter A. Crawford (UMN: University of Minnesota)H-Index: 33
view all 6 authors...
: Sodium glucose co-transporter 2 (SGLT2) inhibitors have been associated with increased serum ketone body levels in patients with type 2 diabetes mellitus (T2DM). In the present analysis we evaluated serum ketone body levels and variability in 1278 Japanese patients with T2DM treated with canagliflozin 100 or 200 mg. Similar mean increases in ketone body concentrations of ~2-fold were seen with both canagliflozin doses. The median (interquartile range) percent change from baseline was 62% (0;18...
23 CitationsSource
#1Serge Jabbour (Thomas Jefferson University)H-Index: 25
#2Jochen Seufert (University of Freiburg)H-Index: 32
Last. Anna Maria Langkilde (AstraZeneca)H-Index: 32
view all 6 authors...
Aim: To evaluate the safety and tolerability of dapagliflozin, a highly selective sodium-glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus (T2DM). Methods: Data were pooled from 13 placebo-controlled trials of up to 24weeks' duration (dapagliflozin, n=2360; placebo, n=2295). Larger placebo-/comparator-controlled pools of 21 (≤208weeks; dapagliflozin, n=5936; control, n=3403) and 30 trials (≥12weeks; dapagliflozin, n=9195; control, n=4629) assessed the rare adverse eve...
79 CitationsSource
#1Jenny E. Blau (NIH: National Institutes of Health)H-Index: 11
#2Sri Harsha Tella (NIH: National Institutes of Health)H-Index: 16
Last. Kristina I. Rother (NIH: National Institutes of Health)H-Index: 45
view all 4 authors...
Background Regulatory agencies have concluded that sodium glucose cotransporter 2 (SGLT2) inhibitors lead to ketoacidosis, but published literature on this point remains controversial. Methods We searched the FDA Adverse Event Reporting System (FAERS) for reports of acidosis in patients treated with canagliflozin, dapagliflozin, or empagliflozin (from the date of each drug's FDA approval until May 15, 2015). We compared the number of SGLT2 inhibitor-related reports to reports of acidosis in pati...
74 CitationsSource
Sodium-glucose cotransporter-2 (SGLT2) is selectively expressed in the human kidney, where it executes reabsorption of filtered glucose with a high capacity; it may be overactive in patients with diabetes, especially in the early, hyperfiltering stage of the disease. As a therapeutic target, SGLT2 has been successfully engaged by orally active, selective agents. Initially developed as antihyperglycemic drugs, SGLT2 inhibitors have deployed a range of in vivo actions. Consequences of their primar...
131 CitationsSource
#1Bruce NealH-Index: 116
#2Vlado PerkovicH-Index: 93
Last. David R. Matthews (University of Oxford)H-Index: 84
view all 10 authors...
BackgroundCanagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. MethodsThe CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin o...
3,149 CitationsSource
#1Daisuke YabeH-Index: 35
#2Masahiro IwasakiH-Index: 11
Last. Yutaka SeinoH-Index: 87
view all 10 authors...
This study investigated the safety and efficacy of the sodium-glucose co-transporter-2 (SGLT2) inhibitor luseogliflozin with differing carbohydrate intakes in Japanese individuals with type 2 diabetes (T2D). Participants were randomly assigned to 3 carbohydrate-adjusted meals for 14 days (days 1-14; a high carbohydrate [HC; 55% total energy carbohydrate] and high glycaemic index [HGI] meal; an HC [55% total energy carbohydrate] and low glycaemic index [LGI] meal; or a low carbohydrate [LC; 40% t...
41 CitationsSource
#1Juan P. FriasH-Index: 26
#2Cristian Guja (UMFCD: Carol Davila University of Medicine and Pharmacy)H-Index: 23
Last. Serge Jabbour (Thomas Jefferson University)H-Index: 25
view all 7 authors...
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce glycaemia and weight, and improve cardiovascular risk factors via different mechanisms. We aimed to compare the efficacy and safety of co-initiation of the GLP-1 receptor agonist exenatide and the SGLT2 inhibitor dapagliflozin with exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled by metformin. Methods DURATION-8 was a 28 week,...
216 CitationsSource
#2Bruce A. Perkins (U of T: University of Toronto)H-Index: 63
Last. David Z.I. Cherney (U of T: University of Toronto)H-Index: 45
view all 5 authors...
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their unique glycosuric...
550 CitationsSource
#1Ele FerranniniH-Index: 110
#2Michael Mark (Boehringer Ingelheim)H-Index: 25
Last. Eric Mayoux (Boehringer Ingelheim)H-Index: 20
view all 3 authors...
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in bl...
523 CitationsSource
Cited By3
#1Xingyun Zhu (PKU: Peking University)H-Index: 1
#2Chu Lin (PKU: Peking University)H-Index: 3
Last. Linong Ji (PKU: Peking University)H-Index: 50
view all 6 authors...
Increased glucagon level was hypothesized to participate in the ketoacidosis associated with sodium-glucose co-transporter 2 inhibitors (SGLT2i) treatment. However, the effect of SGLT2i on glucagon remains controversial. Hence, we conducted this meta-analysis to assess the overall effect of SGLT2i treatment on plasma fasting glucagon level in patients with diabetes. PubMed/MEDLINE, Embase, and Cochrane databases were searched for studies published before August 2020. Clinical trials in patients ...
#1Tamara Y. MilderH-Index: 5
#2Sophie L. Stocker (UNSW: University of New South Wales)H-Index: 22
Last. Jerry R. Greenfield (UNSW: University of New South Wales)H-Index: 45
view all 4 authors...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a major advance in the fields of diabetology, nephrology, and cardiology. The cardiovascular and renal benefits of SGLT2 inhibitors are likely largely independent of their glycaemic effects, and this understanding is central to the use of these agents in the high-risk population of people with type 2 diabetes and chronic kidney disease. There are a number of potential safety issues associated with the use of SGLT2 inhibitors. These include th...
5 CitationsSource
The rationale of using a combination of a GLP-1RA plus SGLT- 2 inhibitor relies on many factors. First, these 2 classes...